Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-004 OLE in C9orf72-associated ALS and FTD
NCT05683860Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of WVE-004 in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), sponsored by Wave Life Sciences. Primary endpoint: Number of Occurrences of Participants With Adverse Events (AEs) Severe AEs, Serious Adverse Events (SAEs), and Withdrawals Due to AEs at 24 weeks. Started Dec 2022; status: terminated.
02
Drugs
WVE-004
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT05683860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683860.